🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

217 results for “Merck Sharp and Dohme” Clear

  1. A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.

    Merck Sharp and Dohme

    Infertility

    phase 1 other active

    1 trial

  2. A Single-Ascending-Dose Study of MK6916 in Healthy Participants

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  3. A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

  4. A clinical study of MK-0472 in people with solid tumors (MK-0472-001)

    Merck Sharp and Dohme

    Malignant Neoplasm - Solid Tumors

    phase 1 other active

    1 trial

  5. A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)

    Merck Sharp and Dohme

    Systemic lupus erythematosus, Rheumatoid arthritis

    phase 1 other active

    1 trial

  6. A clinical study of MK-1289 in healthy adult men (MK-1289-001)

    Merck Sharp and Dohme

    COVID-19 Infection

    phase 1 other active

    1 trial

  7. A clinical study of MK-1403 in healthy men (MK-1403-004)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  8. A clinical study of MK-1403 in healthy people (MK-1403-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  9. A clinical study of MK-2420 in healthy men (MK-2420-003)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  10. A clinical study of MK-2420 in healthy people (MK-2420-002)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  11. A clinical study of MK-2828 in healthy people (MK-2828-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  12. A clinical study of MK-2828 in healthy people (MK-2828-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  13. A clinical study of MK-3214 in healthy people (MK-3214-001)

    Merck Sharp and Dohme

    Hypercholesterolaemia

    phase 1 other active

    1 trial

  14. A clinical study of MK-3508 in healthy people (MK-3508-006)

    Merck Sharp and Dohme

    Respiratory syncytial virus infection

    phase 1 other active

    1 trial

  15. A clinical study of MK-4082 in healthy people (MK-4082-001)

    Merck Sharp and Dohme

    Weight management

    phase 1 other active

    1 trial

  16. A clinical study of MK-4646 in healthy people (MK-4646-002)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  17. A clinical study of MK-4646 in people with HIV (MK-4646-003)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  18. A clinical study of MK-5661 and placebo in healthy people (MK-5661-006)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  19. A clinical study of MK-5661 in healthy people (MK-5661-007)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  20. A clinical study of MK-6050 in healthy people (MK-6050-001)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  21. A clinical study of MK-6916 and placebo in healthy people (MK-6916-003)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  22. A clinical study of MK-6916 in healthy people (MK-6916-002)

    Merck Sharp and Dohme

    Acute and Chronic Pain

    phase 1 other active

    1 trial

  23. A clinical study of MK-6916 in healthy people (MK-6916-006)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  24. A clinical study of MK-7228 in healthy men (MK-7228-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources